Voyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Voyager Therapeutics (NASDAQ:VYGR) posted its quarterly earnings data on Thursday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07, FiscalAI reports. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 53.03%. The business had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $8.79 million.

Voyager Therapeutics Trading Up 2.3%

NASDAQ VYGR traded up $0.09 during trading on Friday, hitting $4.05. 639,686 shares of the company’s stock were exchanged, compared to its average volume of 489,386. The company has a market cap of $244.70 million, a PE ratio of -2.06 and a beta of 1.26. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $5.55. The stock’s 50 day moving average price is $4.04 and its two-hundred day moving average price is $4.06.

Analysts Set New Price Targets

VYGR has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, March 17th. Finally, Wall Street Zen downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total transaction of $53,806.63. Following the completion of the transaction, the chief executive officer owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 61,294 shares of company stock worth $233,241 over the last three months. 6.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VYGR. Invesco Ltd. grew its holdings in shares of Voyager Therapeutics by 28.2% during the fourth quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock worth $456,000 after purchasing an additional 25,522 shares during the last quarter. Sphera Funds Management LTD. grew its holdings in shares of Voyager Therapeutics by 70.1% during the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock worth $1,335,000 after purchasing an additional 140,000 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $120,000. Opaleye Management Inc. bought a new stake in Voyager Therapeutics during the 4th quarter worth approximately $4,704,000. Finally, Jump Financial LLC bought a new stake in Voyager Therapeutics during the 4th quarter worth approximately $143,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.